M
ModeX Therapeutics
Innovative multispecific immunotherapies for cancer and infectious disease
About ModeX Therapeutics
ModeX Therapeutics is a biotechnology startup that focuses on developing innovative treatments for complex diseases. The company's unique approach involves combining the power of multiple biologics into single molecules, aiming to create more effective medicines. This approach is particularly relevant for diseases that have multiple facets and require a comprehensive treatment strategy.
ModeX operates in the biotechnology and pharmaceutical industry, serving a broad range of clients, including healthcare providers and patients suffering from complex diseases. The company's business model revolves around research and development of new therapeutic solutions, which are then patented and sold to healthcare providers or directly to patients.
The company generates revenue through the sale of its innovative therapeutic solutions. Additionally, ModeX may also earn income through strategic partnerships with other pharmaceutical companies, licensing its technology, or receiving funding for specific research projects.
ModeX is led by a team of experienced professionals who have served in top positions in academia, government, and industry. This includes co-founders Dr. Elias Zerhouni and Dr. Gary Nabel, who have extensive experience in biomedical imaging, engineering, and academic research. The team's collective expertise and experience position the company well for future growth and innovation in the biotechnology sector.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2020
- Headquarters
- Natick, United States
- Employees
- 76
- Open positions
- 2
- Dealroom signal
- 87.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Oct 2024 | $35M | — | US Department of Health and Human Services | ↗ |
| GROWTH EQUITY VCOther financing | Dec 2023 | $168M | — | US Biomedical Advanced Research and Development Authority | ↗ |
Growth signals
Latest recorded traffic for ModeX Therapeutics is 4.5K monthly website visits, up 32.4% over the last three months. ModeX Therapeutics's team grew 181.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US Department of Health and Human Services
Series B and later1 investor entered at this stage
US Biomedical Advanced Research and Development Authority
Other known investors1 additional known investor
OPKO Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ModeX Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ModeX Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.